Novel Kv2.1 and Kv2.2 inhibitor

Prodrug of INDY, a novel potent ATP-competitive Dyrk1A inhibitor

2OH-BNPP1 is an inhibitor of BUB1 kinase, a Ser/Thr kinase, used for the treatment of cancer.

Potent activator of SHIP-1 inducing apoptosis of the cancer cell lines in vitro in both a time and dose dependant manner

10-Hydroxycanthin-6-one is an antileukemic canthin-6-one alkaloid from Brucea antidysenterica. Antitumor agent.

Novel inhibitor of TRPM6, promoting mesoderm and definitive endoderm differentiation of human embryonic stem cells through alteration of magnesium homeostasis

Inhibitor of of the metalloproteinase ADAM17; Inhibitor of the constitutive and the PMA-inducible CX3CL1 cleavage, blocking TACE as well as ADAM10

preQ1 is a precursor in the biosynthesis of queuosine, a bacterial nucleoside incorporated into tRNA by tRNA transglycosylase. preQ1 binds to an aptamer domain on tRNA that acts as a riboswitch to repress gene expression.

Selective inhibitor of NADPH oxidase activity in low micromolar concentrations, interfering neither with ROS detection nor with XOD or eNOS activities

TSPC is an inhibitor for GA perception by in vitro and in planta evaluations.

ML-261 is a thienopyrrole-5-carboxamide that inhibits lipid droplet formation.

Potent, reversible, and ATP-competitive inhibitor of human Thymidylate kinase (TMPK)

Novel HCN4 CLP ligand, modulating channel function and completely abolishing the cAMP-induced shift in V1/2

Novel, more stable resveratrol analog, protecting cardiac against mitochondrial damage following H/R, thereby suppressing injury

HAT Inhibitor II is a novel p300/CBP-selective histone acetyltransferase inhibitor.Histone Acetyltransferase Inhibitor II is a potent and cell permeable p300 inhibitor, with an IC50 of 5µM; Histone Acetyltransferase Inhibitor II can be used in cancer research.

Cell permeable cAMP analog, acting as a cardiac stimulant and inhibiting phosphodiesterase

Inhibitor of ventricular tachyarrhythmias in intact mouse and rabbit ventricles by the suppression of SCaEs, independent of beta-blocking activity

Novel inhibitor of the VP40 matrix protein

Novel fluorescent tamoxifen derivative with unique SERM-like properties

Novel blood brain barrier (BBB) penetrable two-photon imaging probe, labelling plaques and cerebral amyloid angiopathies (CAAs)

ATP competitive tyrosine kinase inhibitor

SBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD+ in mice.